Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2016 Aug 1.

Published in final edited form as: Osteoarthritis Cartilage. 2015 Mar 20;23(8):1254–1266. doi: 10.1016/j.joca.2015.02.778

ADAMTS-5 mAb treatment suppresses joint disease severity in a mouse model of osteoarthritis. Mice treated prophylactically with anti-ADAMTS-5 (1x/week, i.p. 10–16 mg/kg) were protected from developing (a) histologic cartilage degeneration (two independent studies shown, n=8–10 animals/group each with two DMM knees/animal, although not all knees in study 2 could be scored due to isolated tissue processing errors and in one group loss of a single mouse between surgery and treatment commencement, as demonstrated by individual knee symbols in each group ranging from 15–19/group). Representative toluidine blue stained knee joint sections are shown for each study group. (b) Mice treated prophylactically with anti-ADAMTS5 mAb (1x/week, i.p. 10 mg/kg) were protected from developing mechanical allodynia through 8 weeks post DMM, *** p<0.001 vs time 0, n=12/group. Mean ±95% CI. (c) Prophylactic treatment with anti-ADAMTS5 mAb also protected mice from macrophage infiltration (F4/80 marker) into the DRG at 8 weeks post DMM. Arrows indicate examples of infiltrating macrophages in the DMM control and Isotype control mAb (IgG1) conditions.

ADAMTS-5 mAb treatment suppresses joint disease severity in a mouse model of osteoarthritis. Mice treated prophylactically with anti-ADAMTS-5 (1x/week, i.p. 10–16 mg/kg) were protected from developing (a) histologic cartilage degeneration (two independent studies shown, n=8–10 animals/group each with two DMM knees/animal, although not all knees in study 2 could be scored due to isolated tissue processing errors and in one group loss of a single mouse between surgery and treatment commencement, as demonstrated by individual knee symbols in each group ranging from 15–19/group). Representative toluidine blue stained knee joint sections are shown for each study group. (b) Mice treated prophylactically with anti-ADAMTS5 mAb (1x/week, i.p. 10 mg/kg) were protected from developing mechanical allodynia through 8 weeks post DMM, *** p<0.001 vs time 0, n=12/group. Mean ±95% CI. (c) Prophylactic treatment with anti-ADAMTS5 mAb also protected mice from macrophage infiltration (F4/80 marker) into the DRG at 8 weeks post DMM. Arrows indicate examples of infiltrating macrophages in the DMM control and Isotype control mAb (IgG1) conditions.